FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970401035> ?p ?o ?g. }

• W1970401035 endingPage "262" @default.
• W1970401035 startingPage "262" @default.
• W1970401035 abstract "In her May 4 news item, Sarah Ramsay1Ramsay S Global Fund makes historic first round of payments.Lancet. 2002; 359: 1581-1582Summary Full Text Full Text PDF PubMed Google Scholar reports that the Global Fund to Fight AIDS, Tuberculosis, and Malaria falls lamentably short of the US$7–10 billion per year that the UN has estimated is necessary to tackle HIV/AIDS alone. In the first round of fund disbursement US$380 million were granted to 40 programmes over 2 years.2http://www.globalfundatm.orgGoogle Scholar A substantial portion of these funds will be used to procure drugs, including antiretrovirals.Although the Fund has made explicit its support for the Doha declaration of October, 2001, on the Trade-Related Intellectual Property Rights (TRIPS) agreement and public health, confusion seems to remain as to acceptable sources of drugs. The application from Malawi stated: “…we are assuming that the Global Fund will only finance patented drugs. This is in line with consultations with WHO and the donor community and initial documents from the Technical Support Secretariat3The Global Fund for AIDS, Tuberculosis and MalariaInterim Secretariat. Malawi integrated national response, 2002: 74.http://www.cid.harvard.edu/gf/docs/10-3-2002.PDFGoogle Scholar”.As an intergovernmental initiative of substantial influence, it is essential that the Fund promotes policies that encourage equitable and sustainable access to essential medicines. It has the potential to encourage efforts to establish systematic equity pricing and promote access to medicines, including the development of sustainable tiered pricing systems and the use of homeproduced or imported generic products. It also has the potential to discourage countries from making use of generic products and TRIPS safeguards, and so undermine the intent of the Doha declaration, by effectively subsidising the use of high-priced branded products.A recent consensus statement from 12 major health non-governmental organisations defines several moves that are required from the Fund if it is to meet its potential in promotion of access to health care in developing countries.4NGO position paper on the Global Fund.http://www.msf.org/content/page.cfm?articleid=DCE8A7CD-1079-487F-98E99510D495F704Google ScholarThe Fund should publicise its strong support for the Doha declaration, and issue guidelines to help countries make appropriate use of the provisions outlined in the declaration in their proposals. Efforts to introduce legislation to support equity pricing, and the use of the TRIPS safeguards, if relevant, should be supported by the Fund working with relevant intergovernmental organisations.An explicit commitment should be made to support the provision of quality products by the most affordable and most sustainable means, including systematic equity pricing through tiered pricing systems and the use of generic supplies, accessed where necessary through the issue of voluntary or compulsory licences. This should form part of the criteria by which proposals are considered.WHO's work on pre-qualification of suppliers of affordable medicines will facilitate the best use of funding and should be supported by the Fund.5Access to HIV AIDS drugs and diagnostics of acceptable quality: pilot procurement quality and sourcing project. WHO, Geneva2002Google Scholar Furthermore, the Fund should collaborate with intergovernmental bodies in development and use of global or regional bulk purchase mechanisms for these medicines.The Doha declaration makes clear that the TRIPS agreement should be implemented in a way that ensures the right to protect public health and, in particular, to promote access to medicines for all who need them. Indicators for measurement of the success of the Global Fund should include its role in promotion of the practical application of these rights by national governments. In her May 4 news item, Sarah Ramsay1Ramsay S Global Fund makes historic first round of payments.Lancet. 2002; 359: 1581-1582Summary Full Text Full Text PDF PubMed Google Scholar reports that the Global Fund to Fight AIDS, Tuberculosis, and Malaria falls lamentably short of the US$7–10 billion per year that the UN has estimated is necessary to tackle HIV/AIDS alone. In the first round of fund disbursement US$380 million were granted to 40 programmes over 2 years.2http://www.globalfundatm.orgGoogle Scholar A substantial portion of these funds will be used to procure drugs, including antiretrovirals. Although the Fund has made explicit its support for the Doha declaration of October, 2001, on the Trade-Related Intellectual Property Rights (TRIPS) agreement and public health, confusion seems to remain as to acceptable sources of drugs. The application from Malawi stated: “…we are assuming that the Global Fund will only finance patented drugs. This is in line with consultations with WHO and the donor community and initial documents from the Technical Support Secretariat3The Global Fund for AIDS, Tuberculosis and MalariaInterim Secretariat. Malawi integrated national response, 2002: 74.http://www.cid.harvard.edu/gf/docs/10-3-2002.PDFGoogle Scholar”. As an intergovernmental initiative of substantial influence, it is essential that the Fund promotes policies that encourage equitable and sustainable access to essential medicines. It has the potential to encourage efforts to establish systematic equity pricing and promote access to medicines, including the development of sustainable tiered pricing systems and the use of homeproduced or imported generic products. It also has the potential to discourage countries from making use of generic products and TRIPS safeguards, and so undermine the intent of the Doha declaration, by effectively subsidising the use of high-priced branded products. A recent consensus statement from 12 major health non-governmental organisations defines several moves that are required from the Fund if it is to meet its potential in promotion of access to health care in developing countries.4NGO position paper on the Global Fund.http://www.msf.org/content/page.cfm?articleid=DCE8A7CD-1079-487F-98E99510D495F704Google Scholar The Fund should publicise its strong support for the Doha declaration, and issue guidelines to help countries make appropriate use of the provisions outlined in the declaration in their proposals. Efforts to introduce legislation to support equity pricing, and the use of the TRIPS safeguards, if relevant, should be supported by the Fund working with relevant intergovernmental organisations. An explicit commitment should be made to support the provision of quality products by the most affordable and most sustainable means, including systematic equity pricing through tiered pricing systems and the use of generic supplies, accessed where necessary through the issue of voluntary or compulsory licences. This should form part of the criteria by which proposals are considered. WHO's work on pre-qualification of suppliers of affordable medicines will facilitate the best use of funding and should be supported by the Fund.5Access to HIV AIDS drugs and diagnostics of acceptable quality: pilot procurement quality and sourcing project. WHO, Geneva2002Google Scholar Furthermore, the Fund should collaborate with intergovernmental bodies in development and use of global or regional bulk purchase mechanisms for these medicines. The Doha declaration makes clear that the TRIPS agreement should be implemented in a way that ensures the right to protect public health and, in particular, to promote access to medicines for all who need them. Indicators for measurement of the success of the Global Fund should include its role in promotion of the practical application of these rights by national governments." @default.
• W1970401035 created "2016-06-24" @default.
• W1970401035 creator A5022632394 @default.
• W1970401035 creator A5065239574 @default.
• W1970401035 creator A5075535479 @default.
• W1970401035 date "2002-07-01" @default.
• W1970401035 modified "2023-09-26" @default.
• W1970401035 title "First round of payments from the Global Fund" @default.
• W1970401035 cites W2114269034 @default.
• W1970401035 doi "https://doi.org/10.1016/s0140-6736(02)09485-0" @default.
• W1970401035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12133694" @default.
• W1970401035 hasPublicationYear "2002" @default.
• W1970401035 type Work @default.
• W1970401035 sameAs 1970401035 @default.
• W1970401035 citedByCount "1" @default.
• W1970401035 crossrefType "journal-article" @default.
• W1970401035 hasAuthorship W1970401035A5022632394 @default.
• W1970401035 hasAuthorship W1970401035A5065239574 @default.
• W1970401035 hasAuthorship W1970401035A5075535479 @default.
• W1970401035 hasConcept C10138342 @default.
• W1970401035 hasConcept C144133560 @default.
• W1970401035 hasConcept C145097563 @default.
• W1970401035 hasConceptScore W1970401035C10138342 @default.
• W1970401035 hasConceptScore W1970401035C144133560 @default.
• W1970401035 hasConceptScore W1970401035C145097563 @default.
• W1970401035 hasIssue "9328" @default.
• W1970401035 hasLocation W19704010351 @default.
• W1970401035 hasLocation W19704010352 @default.
• W1970401035 hasOpenAccess W1970401035 @default.
• W1970401035 hasPrimaryLocation W19704010351 @default.
• W1970401035 hasRelatedWork W2001977471 @default.
• W1970401035 hasRelatedWork W2117761556 @default.
• W1970401035 hasRelatedWork W2202858142 @default.
• W1970401035 hasRelatedWork W2364179866 @default.
• W1970401035 hasRelatedWork W2490602789 @default.
• W1970401035 hasRelatedWork W3020870324 @default.
• W1970401035 hasRelatedWork W3068018378 @default.
• W1970401035 hasRelatedWork W4220843803 @default.
• W1970401035 hasRelatedWork W4302366091 @default.
• W1970401035 hasRelatedWork W1177370825 @default.
• W1970401035 hasVolume "360" @default.
• W1970401035 isParatext "false" @default.
• W1970401035 isRetracted "false" @default.
• W1970401035 magId "1970401035" @default.
• W1970401035 workType "article" @default.